WEST PALM BEACH, FL -- (MARKET WIRE) -- 04/09/07 -- Hydromedix Group, Inc. (PINKSHEETS: HMXG) is proud to have Dr. Kishore Dass assisting in the prototype development of the appendage pieces relating to the radiation oncology treatment of patients. These appendage pieces focus on the areas of the breast, neck, back, torso, and other areas relating to radiation treatment and will be designed to improve the healing process for radiation patients as well to lessen the pain for patients in between radiation treatments.

About Hydromedix Group, Inc.

Hydromedix (www.hydromedix.com) operates within the 200+ Billion Dollar Medical Devices and Supply Industry and develops medical devices that accelerate the rate of healing of certain types of injuries. Upon completion of development of the products and appropriate testing, HMXG intends to market their products to a diverse market clientele, including medical offices, hospitals, long-term care facilities and physical therapists. Their Patented "Dry Contact Whirlpool Therapy" technology speeds the healing process for post-operative surgical patients, radiation therapy, and the rehabilitating process for injured athletes by applying heat or cold to the injured area in a more efficient and effective manner, thus having the potential to speed up the healing process a considerable amount compared to the traditional healing methods.

Safe Harbor

This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (The "Act"). In particular, when used in the preceding of discussion, the words "pleased," "plan," "confident that," "believe," "expect," or "intent to" and similar conditional expressions are intended to identity forward-looking statements within the meaning of the Act and are subject to the safe harbour created by the Act. Such statements are subject to certain risks and uncertainties and actual results could differ materially from those expressed in any of the forward-looking statements. Such risks and uncertainties include, but are not limited to, market conditions, general acceptance of the company's products and technologies, competitive factors, the ability to successfully complete additional financings and other risks in the company's SEC reports and filings.

CONTACT:

Investment Strategies

Jeremy Hunt

Corporate Consultant

304-523-3980

jhunt@invstrategies.com